Clinical trial · Observational
Three-pronged Centralized Molecular Analysis to Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer
A Multi-institutional Effort With a Three-pronged Centralized Molecular Analysis to Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This multi-center study aims at NTRK fusion testing of all patients with advanced thyroid cancer (any histotype and regardless of stage). The primary objective of this study is to assess the frequency of NTRK fusions in thyroid cancer. The secondary objective of this study is to develop an effective tool (testing) strategy for the detection of NTRK fusions in thyroid tumors, comparing the diagnostic tecniques available (IHC, real-time PCR and NGS).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NTRK fusion assessment | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Frequency of NTRK fusions in thyroid cancer
- timeFrame
- from 01-Jan-2022 to 31-Dec-2023
- description
- To assess the frequency of NTRK fusions in histological sample of tumors by patients affected by thyroid cancer, assessed as the number of tumor harboring NTRK fusion on the total of tumor analized
Secondary outcomes (2)
- measure
- Assesment of the ability of Immunohistochemistry to identify for NTRK fusion
- timeFrame
- from 01-Jan-2022 to 31-Dec-2023
- description
- To assess the ability of Immunohistochemistry to detect NTRK fusion on histological sample (using NGS as comparator)
- measure
- Assesment of the ability of real time PCR to identify for NTRK fusion
- timeFrame
- from 01-Jan-2022 to 31-Dec-2023
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of advanced thyroid cancer (any histotype) * Informed consent. Exclusion Criteria: * Patients with thyroid neoplasms without appropriate material for subsequent immunohistochemical and molecular studies; * Patients with non-advanced thyroid cancer
References
Publications (0)
Data not yet available